港股“子”曰 | 56亿美元利好

每日经济新闻
Jan 13

港股创新药,可能又要热闹起来了。  今天,消息面最大的利好,来自荣昌生物(HK09995)。  荣昌生物昨晚公布了重量级利好:艾伯维(纽约证券交易所代码:ABBV)和荣昌生物宣布签署独家授权许可协议,共同开发、生产以及商业化RC148。  根据协议,艾伯维将获得RC148在大中华区以外地区的独家开发、生产和商业化权利。荣昌生物将获得6.5亿美元的首付款,并有资格获得最高达49.5亿美元的开发、监管...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10